FDA approves Takeda's metastatic colorectal cancer drug

A small molecule, oral targeted therapy for adults with metastatic colorectal cancer (CRC) has been approved by the US Food and Drug Administration (FDA).

Related Keywords

Macau ,China ,United States ,Hong Kong ,American ,Cathy Eng ,Takeda Fruzaqla ,Weiguo Su ,Eli Lilly ,Teresa Bitetti ,Journal Of The American Medical Association ,Hutchmed China ,Vanderbilt University Medical Center ,Prescription Drug Users Fee Act ,Global Oncology Business Unit ,American Medical ,Vanderbilt University Medical ,Clinical Development ,Markets Amp Regulations ,Pis Active Pharmaceutical Ingredients ,Regulations ,Hutchmed ,Colorectal Cancer ,Research ,Makeda ,Clinical Trial ,